Loading…
Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study
Purpose The aim of this study was to evaluate changes in hip geometry parameters following treatment with teriparatide (TPD), denosumab (Dmab) and zoledronate (ZOL) in real-life setting. Methods We studied 249 patients with osteoporosis (OP) with mean [SD] age of 71.5 [11.1] years divided into 3 tre...
Saved in:
| Published in: | Journal of endocrinological investigation 2024-07, Vol.47 (7), p.1667-1677 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c426t-4c7fbf94167101a1b6ebab5effa3dae3c16f732ba303f6bd5fd436d57592260a3 |
| container_end_page | 1677 |
| container_issue | 7 |
| container_start_page | 1667 |
| container_title | Journal of endocrinological investigation |
| container_volume | 47 |
| creator | Jaarah, N. Lam, C. F. J. Lodhia, N. Dulnoan, D. Moore, A. E. Hampson, G. |
| description | Purpose
The aim of this study was to evaluate changes in hip geometry parameters following treatment with teriparatide (TPD), denosumab (Dmab) and zoledronate (ZOL) in real-life setting.
Methods
We studied 249 patients with osteoporosis (OP) with mean [SD] age of 71.5 [11.1] years divided into 3 treatment groups; Group A received TPD;
n
= 55, Group B (Dmab);
n
= 116 and Group C (ZOL);
n
= 78 attending a routine metabolic bone clinic. Bone mineral density (BMD) was measured by DXA at the lumbar spine (LS), total hip (TH) and femoral neck (FN) prior to treatment and after 2 years (Group A), after a mean treatment duration of 3.3 [1.3] years (Group B) and after 1, 2 and 3 doses of ZOL (Group C) to assess treatment response. Hip structural analysis (HSA) was carried out retrospectively from DXA-acquired femur images at the narrow neck (NN), the intertrochanter (IT) and femoral shaft (FS).
Results
Changes in
p
arameters of hip geometry and mechanical strength were seen in the following treatment. Percentage change in cross-sectional area (CSA): 3.56[1.6] %
p
= 0.01 and cross-sectional moment of inertia (CSMI): 4.1[1.8] %
p
= 0.029 increased at the NN only in Group A. Improvement in HSA parameters at the IT were seen in group B: CSA: 3.3[0.67]%
p
|
| doi_str_mv | 10.1007/s40618-023-02280-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11196340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3071987688</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-4c7fbf94167101a1b6ebab5effa3dae3c16f732ba303f6bd5fd436d57592260a3</originalsourceid><addsrcrecordid>eNp9kctu1TAQhiMEoqXwAiyQJTYsCPiS2IlYVKhcpUpsYG059rjHVWIH20EqD8EzM4dTSmHBwvJY8883M_6b5jGjLxil6mXpqGRDS7nAwwfadneaY6Y4bQcxyLu34qPmQSmXlAolBnW_ORIDG9nYyePmx5vgPWSINZiZAMa2FpI8qZDDarKpwcFz4iCmsi1mIiY68j3N4HKKpgJJkezCSkrNm61bRshesYDdmRgsPveQBRBXSIgklQppTTmVUF4RQzKYuZ2DByRs7uphc8-bucCj6_uk-fLu7eezD-35p_cfz16ft7bjsradVX7yY8ekYpQZNkmYzNTj-EY4A8Iy6ZXgkxFUeDm53rtOSNerfuRcUiNOmtMDd92mBZzF_XF0veawmHylkwn670wMO32RvmnG2ChFR5Hw7JqQ09cNStVLKBbm2URIW9F8ZLznElui9Ok_0su05Yj7aUEVGwclhwFV_KCy-Dklg7-ZhlG991sf_Nbot_7lt-6w6MntPW5KfhuMAnEQFEzFC8h_ev8H-xMhNbpQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3071987688</pqid></control><display><type>article</type><title>Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study</title><source>Springer Link</source><creator>Jaarah, N. ; Lam, C. F. J. ; Lodhia, N. ; Dulnoan, D. ; Moore, A. E. ; Hampson, G.</creator><creatorcontrib>Jaarah, N. ; Lam, C. F. J. ; Lodhia, N. ; Dulnoan, D. ; Moore, A. E. ; Hampson, G.</creatorcontrib><description>Purpose
The aim of this study was to evaluate changes in hip geometry parameters following treatment with teriparatide (TPD), denosumab (Dmab) and zoledronate (ZOL) in real-life setting.
Methods
We studied 249 patients with osteoporosis (OP) with mean [SD] age of 71.5 [11.1] years divided into 3 treatment groups; Group A received TPD;
n
= 55, Group B (Dmab);
n
= 116 and Group C (ZOL);
n
= 78 attending a routine metabolic bone clinic. Bone mineral density (BMD) was measured by DXA at the lumbar spine (LS), total hip (TH) and femoral neck (FN) prior to treatment and after 2 years (Group A), after a mean treatment duration of 3.3 [1.3] years (Group B) and after 1, 2 and 3 doses of ZOL (Group C) to assess treatment response. Hip structural analysis (HSA) was carried out retrospectively from DXA-acquired femur images at the narrow neck (NN), the intertrochanter (IT) and femoral shaft (FS).
Results
Changes in
p
arameters of hip geometry and mechanical strength were seen in the following treatment. Percentage change in cross-sectional area (CSA): 3.56[1.6] %
p
= 0.01 and cross-sectional moment of inertia (CSMI): 4.1[1.8] %
p
= 0.029 increased at the NN only in Group A. Improvement in HSA parameters at the IT were seen in group B: CSA: 3.3[0.67]%
p
< 0.001, cortical thickness (Co Th): 2.8[0.78]%
p
= 0.001, CSMI: 5.9[1.3]%
p
< 0.001, section modulus (Z):6.2[1.1]%
p
< 0.001 and buckling ratio (BR): − 3.0[0.86]%
p
= 0.001 with small changes at the FS: CSA: 1.2[0.4]%
p
= 0.005, Z:1.6 [0.76]%,
p
= 0.04
.
Changes at the IT were also seen in Group C (after 2 doses): CSA: 2.5[0.77]%
p
= 0.017, Co Th: 2.4[0.84]%
p
= 0.012, CSMI: 3.9[1.3]%
p
=
0.017
, Z:5.2[1.16]%
p
< 0.001 and BR: − 3.1[0.88]%
p
= 0.001 and at the NN (following 3 doses): outer diameter (OD): 4.0[1.4]%
p
= 0.0005, endocortical diameter(ED): 4.3[1.67%
p
= 0.009, CSA:5.2[1.8]%
p
= 0.003, CSMI: 9.3[3.8]%
p
= 0.019
.
Conclusions
Analysis of the effect of OP therapies on hip geometry is useful in understanding the mechanisms of their anti-fracture effect and may provide additional information on their efficacy.</description><identifier>ISSN: 1720-8386</identifier><identifier>ISSN: 0391-4097</identifier><identifier>EISSN: 1720-8386</identifier><identifier>DOI: 10.1007/s40618-023-02280-4</identifier><identifier>PMID: 38191946</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject><![CDATA[Absorptiometry, Photon ; Aged ; Aged, 80 and over ; Bone Density - drug effects ; Bone Density Conservation Agents - administration & dosage ; Bone Density Conservation Agents - therapeutic use ; Bone mineral density ; Denosumab - administration & dosage ; Denosumab - therapeutic use ; Diphosphonates - administration & dosage ; Diphosphonates - therapeutic use ; Dual energy X-ray absorptiometry ; Endocrinology ; Female ; Femur ; Follow-Up Studies ; Geometry ; Hip ; Humans ; Internal Medicine ; Male ; Mechanical properties ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Original ; Original Article ; Osteoporosis ; Osteoporosis - drug therapy ; Osteoporosis - pathology ; Parathyroid hormone ; Retrospective Studies ; Spine (lumbar) ; Teriparatide - administration & dosage ; Teriparatide - pharmacology ; Teriparatide - therapeutic use ; Zoledronic acid ; Zoledronic Acid - administration & dosage ; Zoledronic Acid - pharmacology ; Zoledronic Acid - therapeutic use]]></subject><ispartof>Journal of endocrinological investigation, 2024-07, Vol.47 (7), p.1667-1677</ispartof><rights>Crown 2024</rights><rights>2024. Crown.</rights><rights>Crown 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-4c7fbf94167101a1b6ebab5effa3dae3c16f732ba303f6bd5fd436d57592260a3</cites><orcidid>0000-0001-8465-5247</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27900,27901</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38191946$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jaarah, N.</creatorcontrib><creatorcontrib>Lam, C. F. J.</creatorcontrib><creatorcontrib>Lodhia, N.</creatorcontrib><creatorcontrib>Dulnoan, D.</creatorcontrib><creatorcontrib>Moore, A. E.</creatorcontrib><creatorcontrib>Hampson, G.</creatorcontrib><title>Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study</title><title>Journal of endocrinological investigation</title><addtitle>J Endocrinol Invest</addtitle><addtitle>J Endocrinol Invest</addtitle><description>Purpose
The aim of this study was to evaluate changes in hip geometry parameters following treatment with teriparatide (TPD), denosumab (Dmab) and zoledronate (ZOL) in real-life setting.
Methods
We studied 249 patients with osteoporosis (OP) with mean [SD] age of 71.5 [11.1] years divided into 3 treatment groups; Group A received TPD;
n
= 55, Group B (Dmab);
n
= 116 and Group C (ZOL);
n
= 78 attending a routine metabolic bone clinic. Bone mineral density (BMD) was measured by DXA at the lumbar spine (LS), total hip (TH) and femoral neck (FN) prior to treatment and after 2 years (Group A), after a mean treatment duration of 3.3 [1.3] years (Group B) and after 1, 2 and 3 doses of ZOL (Group C) to assess treatment response. Hip structural analysis (HSA) was carried out retrospectively from DXA-acquired femur images at the narrow neck (NN), the intertrochanter (IT) and femoral shaft (FS).
Results
Changes in
p
arameters of hip geometry and mechanical strength were seen in the following treatment. Percentage change in cross-sectional area (CSA): 3.56[1.6] %
p
= 0.01 and cross-sectional moment of inertia (CSMI): 4.1[1.8] %
p
= 0.029 increased at the NN only in Group A. Improvement in HSA parameters at the IT were seen in group B: CSA: 3.3[0.67]%
p
< 0.001, cortical thickness (Co Th): 2.8[0.78]%
p
= 0.001, CSMI: 5.9[1.3]%
p
< 0.001, section modulus (Z):6.2[1.1]%
p
< 0.001 and buckling ratio (BR): − 3.0[0.86]%
p
= 0.001 with small changes at the FS: CSA: 1.2[0.4]%
p
= 0.005, Z:1.6 [0.76]%,
p
= 0.04
.
Changes at the IT were also seen in Group C (after 2 doses): CSA: 2.5[0.77]%
p
= 0.017, Co Th: 2.4[0.84]%
p
= 0.012, CSMI: 3.9[1.3]%
p
=
0.017
, Z:5.2[1.16]%
p
< 0.001 and BR: − 3.1[0.88]%
p
= 0.001 and at the NN (following 3 doses): outer diameter (OD): 4.0[1.4]%
p
= 0.0005, endocortical diameter(ED): 4.3[1.67%
p
= 0.009, CSA:5.2[1.8]%
p
= 0.003, CSMI: 9.3[3.8]%
p
= 0.019
.
Conclusions
Analysis of the effect of OP therapies on hip geometry is useful in understanding the mechanisms of their anti-fracture effect and may provide additional information on their efficacy.</description><subject>Absorptiometry, Photon</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone mineral density</subject><subject>Denosumab - administration & dosage</subject><subject>Denosumab - therapeutic use</subject><subject>Diphosphonates - administration & dosage</subject><subject>Diphosphonates - therapeutic use</subject><subject>Dual energy X-ray absorptiometry</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Femur</subject><subject>Follow-Up Studies</subject><subject>Geometry</subject><subject>Hip</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Mechanical properties</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Original Article</subject><subject>Osteoporosis</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - pathology</subject><subject>Parathyroid hormone</subject><subject>Retrospective Studies</subject><subject>Spine (lumbar)</subject><subject>Teriparatide - administration & dosage</subject><subject>Teriparatide - pharmacology</subject><subject>Teriparatide - therapeutic use</subject><subject>Zoledronic acid</subject><subject>Zoledronic Acid - administration & dosage</subject><subject>Zoledronic Acid - pharmacology</subject><subject>Zoledronic Acid - therapeutic use</subject><issn>1720-8386</issn><issn>0391-4097</issn><issn>1720-8386</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1TAQhiMEoqXwAiyQJTYsCPiS2IlYVKhcpUpsYG059rjHVWIH20EqD8EzM4dTSmHBwvJY8883M_6b5jGjLxil6mXpqGRDS7nAwwfadneaY6Y4bQcxyLu34qPmQSmXlAolBnW_ORIDG9nYyePmx5vgPWSINZiZAMa2FpI8qZDDarKpwcFz4iCmsi1mIiY68j3N4HKKpgJJkezCSkrNm61bRshesYDdmRgsPveQBRBXSIgklQppTTmVUF4RQzKYuZ2DByRs7uphc8-bucCj6_uk-fLu7eezD-35p_cfz16ft7bjsradVX7yY8ekYpQZNkmYzNTj-EY4A8Iy6ZXgkxFUeDm53rtOSNerfuRcUiNOmtMDd92mBZzF_XF0veawmHylkwn670wMO32RvmnG2ChFR5Hw7JqQ09cNStVLKBbm2URIW9F8ZLznElui9Ok_0su05Yj7aUEVGwclhwFV_KCy-Dklg7-ZhlG991sf_Nbot_7lt-6w6MntPW5KfhuMAnEQFEzFC8h_ev8H-xMhNbpQ</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Jaarah, N.</creator><creator>Lam, C. F. J.</creator><creator>Lodhia, N.</creator><creator>Dulnoan, D.</creator><creator>Moore, A. E.</creator><creator>Hampson, G.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8465-5247</orcidid></search><sort><creationdate>20240701</creationdate><title>Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study</title><author>Jaarah, N. ; Lam, C. F. J. ; Lodhia, N. ; Dulnoan, D. ; Moore, A. E. ; Hampson, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-4c7fbf94167101a1b6ebab5effa3dae3c16f732ba303f6bd5fd436d57592260a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Absorptiometry, Photon</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone mineral density</topic><topic>Denosumab - administration & dosage</topic><topic>Denosumab - therapeutic use</topic><topic>Diphosphonates - administration & dosage</topic><topic>Diphosphonates - therapeutic use</topic><topic>Dual energy X-ray absorptiometry</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Femur</topic><topic>Follow-Up Studies</topic><topic>Geometry</topic><topic>Hip</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Mechanical properties</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Original Article</topic><topic>Osteoporosis</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - pathology</topic><topic>Parathyroid hormone</topic><topic>Retrospective Studies</topic><topic>Spine (lumbar)</topic><topic>Teriparatide - administration & dosage</topic><topic>Teriparatide - pharmacology</topic><topic>Teriparatide - therapeutic use</topic><topic>Zoledronic acid</topic><topic>Zoledronic Acid - administration & dosage</topic><topic>Zoledronic Acid - pharmacology</topic><topic>Zoledronic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jaarah, N.</creatorcontrib><creatorcontrib>Lam, C. F. J.</creatorcontrib><creatorcontrib>Lodhia, N.</creatorcontrib><creatorcontrib>Dulnoan, D.</creatorcontrib><creatorcontrib>Moore, A. E.</creatorcontrib><creatorcontrib>Hampson, G.</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of endocrinological investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jaarah, N.</au><au>Lam, C. F. J.</au><au>Lodhia, N.</au><au>Dulnoan, D.</au><au>Moore, A. E.</au><au>Hampson, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study</atitle><jtitle>Journal of endocrinological investigation</jtitle><stitle>J Endocrinol Invest</stitle><addtitle>J Endocrinol Invest</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>47</volume><issue>7</issue><spage>1667</spage><epage>1677</epage><pages>1667-1677</pages><issn>1720-8386</issn><issn>0391-4097</issn><eissn>1720-8386</eissn><abstract>Purpose
The aim of this study was to evaluate changes in hip geometry parameters following treatment with teriparatide (TPD), denosumab (Dmab) and zoledronate (ZOL) in real-life setting.
Methods
We studied 249 patients with osteoporosis (OP) with mean [SD] age of 71.5 [11.1] years divided into 3 treatment groups; Group A received TPD;
n
= 55, Group B (Dmab);
n
= 116 and Group C (ZOL);
n
= 78 attending a routine metabolic bone clinic. Bone mineral density (BMD) was measured by DXA at the lumbar spine (LS), total hip (TH) and femoral neck (FN) prior to treatment and after 2 years (Group A), after a mean treatment duration of 3.3 [1.3] years (Group B) and after 1, 2 and 3 doses of ZOL (Group C) to assess treatment response. Hip structural analysis (HSA) was carried out retrospectively from DXA-acquired femur images at the narrow neck (NN), the intertrochanter (IT) and femoral shaft (FS).
Results
Changes in
p
arameters of hip geometry and mechanical strength were seen in the following treatment. Percentage change in cross-sectional area (CSA): 3.56[1.6] %
p
= 0.01 and cross-sectional moment of inertia (CSMI): 4.1[1.8] %
p
= 0.029 increased at the NN only in Group A. Improvement in HSA parameters at the IT were seen in group B: CSA: 3.3[0.67]%
p
< 0.001, cortical thickness (Co Th): 2.8[0.78]%
p
= 0.001, CSMI: 5.9[1.3]%
p
< 0.001, section modulus (Z):6.2[1.1]%
p
< 0.001 and buckling ratio (BR): − 3.0[0.86]%
p
= 0.001 with small changes at the FS: CSA: 1.2[0.4]%
p
= 0.005, Z:1.6 [0.76]%,
p
= 0.04
.
Changes at the IT were also seen in Group C (after 2 doses): CSA: 2.5[0.77]%
p
= 0.017, Co Th: 2.4[0.84]%
p
= 0.012, CSMI: 3.9[1.3]%
p
=
0.017
, Z:5.2[1.16]%
p
< 0.001 and BR: − 3.1[0.88]%
p
= 0.001 and at the NN (following 3 doses): outer diameter (OD): 4.0[1.4]%
p
= 0.0005, endocortical diameter(ED): 4.3[1.67%
p
= 0.009, CSA:5.2[1.8]%
p
= 0.003, CSMI: 9.3[3.8]%
p
= 0.019
.
Conclusions
Analysis of the effect of OP therapies on hip geometry is useful in understanding the mechanisms of their anti-fracture effect and may provide additional information on their efficacy.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38191946</pmid><doi>10.1007/s40618-023-02280-4</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8465-5247</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1720-8386 |
| ispartof | Journal of endocrinological investigation, 2024-07, Vol.47 (7), p.1667-1677 |
| issn | 1720-8386 0391-4097 1720-8386 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11196340 |
| source | Springer Link |
| subjects | Absorptiometry, Photon Aged Aged, 80 and over Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - therapeutic use Bone mineral density Denosumab - administration & dosage Denosumab - therapeutic use Diphosphonates - administration & dosage Diphosphonates - therapeutic use Dual energy X-ray absorptiometry Endocrinology Female Femur Follow-Up Studies Geometry Hip Humans Internal Medicine Male Mechanical properties Medicine Medicine & Public Health Metabolic Diseases Middle Aged Original Original Article Osteoporosis Osteoporosis - drug therapy Osteoporosis - pathology Parathyroid hormone Retrospective Studies Spine (lumbar) Teriparatide - administration & dosage Teriparatide - pharmacology Teriparatide - therapeutic use Zoledronic acid Zoledronic Acid - administration & dosage Zoledronic Acid - pharmacology Zoledronic Acid - therapeutic use |
| title | Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T10%3A11%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20effects%20of%20teriparatide,%20denosumab%20and%20zoledronate%20on%20hip%20structural%20and%20mechanical%20parameters%20in%20osteoporosis;%20a%20real-life%20study&rft.jtitle=Journal%20of%20endocrinological%20investigation&rft.au=Jaarah,%20N.&rft.date=2024-07-01&rft.volume=47&rft.issue=7&rft.spage=1667&rft.epage=1677&rft.pages=1667-1677&rft.issn=1720-8386&rft.eissn=1720-8386&rft_id=info:doi/10.1007/s40618-023-02280-4&rft_dat=%3Cproquest_pubme%3E3071987688%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c426t-4c7fbf94167101a1b6ebab5effa3dae3c16f732ba303f6bd5fd436d57592260a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3071987688&rft_id=info:pmid/38191946&rfr_iscdi=true |